Hana Geumtu Shows Celltrion’s New Drug Development Capability
viewer
Covid-19 antibody treatment Celltrion (068270)On the 14th, Hana Financial Investment evaluated the ability to develop new drugs. However, it is expected that the effect of improving earnings will be limited.
Researcher Seon Min-jung said, “The antibody treatment announced by Celltrion is a new drug developed by Celltrion itself.” Evaluated.
He continued, “There is a limit to expecting the effect of improving Celltrion’s performance due to Rekirona (Corona 19 antibody treatment).” Although it can be expected, it will be difficult for the market to be marketed in Korea, where the number of corona19 patients is small and the market size is small.”
Researcher Sun also said, “It is expected to enter the US or European market in the future, but only 20% of the antibody treatment system of Regeneron, which has been effective in clinical results, is prescribed at local US hospitals.” The analysis that it is difficult to become a game changer is dominant, and it is time to make a more cold judgment.
/ Reporter Lee Wan [email protected]
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >